Related non-peptide compound
MK-677 / ibutamoren
A non-peptide growth-hormone secretagogue, often discussed alongside peptides.
Also discussed as: Ibutamoren
THE RESEARCH QUESTION
What is being investigated?
Studies have examined GH/IGF-I signalling and specific clinical outcomes.
EVIDENCE SNAPSHOT
Human studies; safety concerns
In a randomised Alzheimer disease trial, increasing IGF-I did not slow disease progression. A favourable biomarker change is not automatically a clinical benefit.
LIMITS & SAFETY
What should you know?
Heart-failure concerns have been reported in susceptible patients.
FOLLOW THE EVIDENCE
Sources & further reading
- MK-677: randomised Alzheimer disease trial (2008) ↗Human trial
- FDA: safety information for bulk substances used in compounding ↗Regulator
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.